摩熵咨询：2024年市场研究专题报告十八-集落刺激因子药物

Core Viewpoint - The report by MoSheng Consulting focuses on colony-stimulating factor (CSF) drugs, analyzing their classification, market landscape, clinical applications, and market trends for 2024. Group 1: Overview of Bone Marrow Suppression and Colony-Stimulating Factors - Chemotherapy is a cornerstone treatment for tumors, but bone marrow suppression is a major adverse effect, leading to neutropenia, thrombocytopenia, and tumor-related anemia [1][9] - Neutropenia, occurring at a high incidence, can affect chemotherapy efficacy and increase the risk of infection and mortality. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) and pegylated rhG-CSF (PEG-rhG-CSF) are effective drugs for preventing and treating neutropenia [1][15] Group 2: Classification and Mechanism of Action of Colony-Stimulating Factors - Colony-stimulating factors mainly include granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). G-CSF promotes hematopoietic stem cell proliferation and regulates neutrophil production [1][12] - G-CSF is further divided into rhG-CSF, PEG-rhG-CSF, and rhGM-CSF, each with different indications, mechanisms of action, and pharmacokinetic characteristics [1][21] Group 3: Market Competition Landscape - The G-CSF market has grown nearly 3.5 times from 2015 to 2023, peaking at 10.31 billion in 2022. PEG-rhG-CSF has a market share of 69.65%, becoming the mainstream product, while rhG-CSF maintains stable sales around 3 billion [2][28] - The domestic rhG-CSF market is competitive, with Qilu Pharmaceutical as the leading company. Currently, seven PEG-rhG-CSF products have been approved for market, and the first-generation products have largely released their volume benefits, with some price declines expected for a second wave of growth [2][26] Group 4: Market Trend Analysis - The PEG-rhG-CSF market is expected to remain relatively stable in the coming years, with only a few products in the pipeline. The development of rhG-CSF in reproductive fields is a future direction, although further research is needed [2][28] - Trastuzumab, as a cyclin-dependent kinase 4/6 inhibitor, can reduce hematological toxicity and the usage rate of G-CSF [2][28]